Trials / Completed
CompletedNCT01675570
A Study of RX-10045 in the Treatment of Dry Eye Disease
A Phase II, Multi-Center, Randomized, Placebo-Controlled, Double-Masked Study of RX-10045 (0.09%) in the Treatment of Dry Eye Disease
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 150 (actual)
- Sponsor
- C.T. Development America, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary purpose of this study is to assess the efficacy, tolerability and safety of RX-10045 Ophthalmic Solution in patients with Dry Eye Disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RX-10045 | One drop of RX-10045 ophthalmic solution will be instilled in each eye, twice a day, approximately 12 hours apart for 28 days. |
| DRUG | Vehicle for RX-10045 | One drop of RX-10045 placebo solution will be instilled in each eye, twice a day, approximately 12 hours apart for 28 days. |
Timeline
- Start date
- 2012-08-01
- Primary completion
- 2012-11-01
- Completion
- 2012-11-01
- First posted
- 2012-08-30
- Last updated
- 2013-02-08
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01675570. Inclusion in this directory is not an endorsement.